238 related articles for article (PubMed ID: 18815050)
1. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
[TBL] [Abstract][Full Text] [Related]
2. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
[TBL] [Abstract][Full Text] [Related]
3. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles.
Boschelli DH; Wu B; Barrios Sosa AC; Chen JJ; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2005 Nov; 15(21):4681-4. PubMed ID: 16125383
[TBL] [Abstract][Full Text] [Related]
5. 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.
Nathan Tumey L; Boschelli DH; Lee J; Chaudhary D
Bioorg Med Chem Lett; 2008 Aug; 18(15):4420-3. PubMed ID: 18606543
[TBL] [Abstract][Full Text] [Related]
6. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
[TBL] [Abstract][Full Text] [Related]
7. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
[TBL] [Abstract][Full Text] [Related]
8. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML
Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships.
Gavrin LK; Green N; Hu Y; Janz K; Kaila N; Li HQ; Tam SY; Thomason JR; Gopalsamy A; Ciszewski G; Cuozzo JW; Hall JP; Hsu S; Telliez JB; Lin LL
Bioorg Med Chem Lett; 2005 Dec; 15(23):5288-92. PubMed ID: 16165349
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.
Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F
J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442
[TBL] [Abstract][Full Text] [Related]
11. Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs.
Boschelli DH; Wu B; Ye F; Durutlic H; Golas JM; Lucas J; Boschelli F
Bioorg Med Chem; 2008 Jan; 16(1):405-12. PubMed ID: 17905586
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis.
Hu Y; Green N; Gavrin LK; Janz K; Kaila N; Li HQ; Thomason JR; Cuozzo JW; Hall JP; Hsu S; Nickerson-Nutter C; Telliez JB; Lin LL; Tam S
Bioorg Med Chem Lett; 2006 Dec; 16(23):6067-72. PubMed ID: 16973359
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M
Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067
[TBL] [Abstract][Full Text] [Related]
14. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
17. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
[TBL] [Abstract][Full Text] [Related]
18. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K
J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026
[TBL] [Abstract][Full Text] [Related]
20. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
